HRP20110497T1 - Postupci za primjenu kompozicija aminopiridina sa produženim oslobađanjem - Google Patents
Postupci za primjenu kompozicija aminopiridina sa produženim oslobađanjem Download PDFInfo
- Publication number
- HRP20110497T1 HRP20110497T1 HR20110497T HRP20110497T HRP20110497T1 HR P20110497 T1 HRP20110497 T1 HR P20110497T1 HR 20110497 T HR20110497 T HR 20110497T HR P20110497 T HRP20110497 T HR P20110497T HR P20110497 T1 HRP20110497 T1 HR P20110497T1
- Authority
- HR
- Croatia
- Prior art keywords
- aminopyridine
- composition
- milligrams
- patient
- multiple sclerosis
- Prior art date
Links
- 150000003927 aminopyridines Chemical class 0.000 title claims abstract 39
- 239000000203 mixture Substances 0.000 title claims abstract 38
- 238000013268 sustained release Methods 0.000 title claims abstract 12
- 239000012730 sustained-release form Substances 0.000 title claims abstract 12
- 238000000034 method Methods 0.000 title 1
- 238000011287 therapeutic dose Methods 0.000 claims abstract 16
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract 13
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 claims 6
- 210000003141 lower extremity Anatomy 0.000 claims 6
- 210000003205 muscle Anatomy 0.000 claims 6
- 229960004979 fampridine Drugs 0.000 claims 3
- ZZYXNRREDYWPLN-UHFFFAOYSA-N pyridine-2,3-diamine Chemical compound NC1=CC=CN=C1N ZZYXNRREDYWPLN-UHFFFAOYSA-N 0.000 claims 3
- 238000013265 extended release Methods 0.000 claims 2
- 230000005021 gait Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Kompozicija aminopiridina sa produženim oslobađanjem za povećanje brzine hoda pacijenta sa multiplom sklerozom, naznačena time što je navedena kompozicija za primjenu kao tretman stabilnom dozom dva puta na dan u terapeutskoj dozi od 15 miligrama ili manje aminopiridina. Patent sadrži još 28 patentnih zahtjeva.
Claims (29)
1. Kompozicija aminopiridina sa produženim oslobađanjem za povećanje brzine hoda pacijenta sa multiplom sklerozom, naznačena time što je navedena kompozicija za primjenu kao tretman stabilnom dozom dva puta na dan u terapeutskoj dozi od 15 miligrama ili manje aminopiridina.
2. Kompozicija aminopiridina sa produženim oslobađanjem za poboljšanje mišićne snage donjih ekstremiteta kod pacijenta sa multiplom sklerozom, naznačena time što je navedena kompozicija za primjenu kao tretman stabilnom dozom dva puta na dan u terapeutskoj dozi od 15 miligrama ili manje aminopiridina.
3. Kompozicija aminopiridina sa produženim oslobađanjem za poboljšanje mišićnog tonusa donjih ekstremiteta kod pacijenta sa multiplom sklerozom, naznačena time što je navedena kompozicija za primjenu kao tretman stabilnom dozom dva puta na dan u terapeutskoj dozi od 15 miligrama ili manje aminopiridina.
4. Kompozicija prema bilo kojem od patentnih zahtjeva 1 do 3, naznačena time što osigurava Cavss od 15 ng/ml do 35 ng/ml.
5. Kompozicija prema bilo kojem od patentnih zahtjeva 1 do 3, naznačena time što je navedena terapeutska doza najmanje 5 miligrama aminopiridina.
6. Kompozicija prema bilo kojem od patentnih zahtjeva 1 do 3, naznačena time što je navedena terapeutska doza 10 do 15 miligrama aminopiridina.
7. Kompozicija prema bilo kojem od patentnih zahtjeva 1 do 3, naznačena time što je navedena terapeutska doza 10 miligrama aminopiridina.
8. Kompozicija prema bilo kojem od patentnih zahtjeva 1 do 3, naznačena time što je navedeni tretman stabilnom dozom po trajanju duži od dva tjedna.
9. Kompozicija prema bilo kojem od patentnih zahtjeva 1 do 7, naznačena time što je navedeni aminopiridin jednak mono- aminopiridin ili di-aminopiridin.
10. Kompozicija prema bilo kojem od patentnih zahtjeva 1 do 8, naznačena time što je navedeni aminopiridin jednak 4-aminopiridin.
11. Kompozicija prema bilo kojem od patentnih zahtjeva 1 do 9, naznačena time što je navedena kompozicija za primjenu svakih 12 sati.
12. Primjena aminopiridina u proizvodnji kompozicije za produženo oslobađanje za povećanje brzine hoda pacijenta sa multiplom sklerozom, naznačena time što je navedena kompozicija za primjenu kao tretman stabilnom dozom dva puta na dan u terapeutskoj dozi od 15 miligrama ili manje aminopiridina.
13. Primjena aminopiridina u proizvodnji kompozicije za produženo oslobađanje za poboljšanje mišićnog tonusa donjih ekstremiteta kod pacijenta sa multiplom sklerozom, naznačena time što je navedena kompozicija za primjenu kao tretman stabilnom dozom dva puta na dan u terapeutskoj dozi od 15 miligrama ili manje aminopiridina.
14. Primjena aminopiridina u proizvodnji kompozicije za produženo oslobađanje za poboljšanje mišićne snage donjih ekstremiteta kod pacijenta sa multiplom sklerozom, naznačena time što navedena kompozicija za primjenu kao tretman stabilnom dozom dva puta na dan u terapeutskoj dozi od 15 miligrama ili manje aminopiridina.
15. Primjena prema bilo kojem od patentnih zahtjeva 12 do 14, naznačena time što osigurava Cavss od 15 ng/ml do 35 ng/ml.
16. Primjena prema bilo kojem od patentnih zahtjeva 12 do 14, naznačena time što je navedena terapeutska doza najmanje 5 miligrama aminopiridina.
17. Primjena prema bilo kojem od patentnih zahtjeva 12 do 14, naznačena time što je navedena terapeutska doza 10 do 15 miligrama aminopiridina.
18. Primjena prema bilo kojem od patentnih zahtjeva 12 do 14, naznačena time što je navedena terapeutska doza 10 miligrama aminopiridina.
19. Primjena prema bilo kojem od patentnih zahtjeva 12 do 14, naznačena time što je navedeni tretman stabilnom dozom po trajanju duži od dva tjedna.
20. Primjena prema bilo kojem od patentnih zahtjeva 12 do 19, naznačena time što je navedeni aminopiridin jednak mono- aminopiridin ili di-aminopiridin.
21. Primjena prema bilo kojem od patentnih zahtjeva 12 do 20, naznačena time što je navedeni aminopiridin jednak 4-aminopiridin.
22. Primjena prema bilo kojem od patentnih zahtjeva 12 do 21, naznačena time što je navedena kompozicija za primjenu svakih 12 sati.
23. Kompozicija aminopiridina sa produženim oslobađanjem za održavanje terapeutski efikasne koncentracije aminopiridina kod pacijenta sa multiplom sklerozom, naznačena time što je navedena kompozicija za primjenu kao tretman stabilnom dozom sa dnevnom terapeutskom dozom od manje od 30 miligrama aminopiridina; i, pri čemu kompozicija aminopiridina sa produženim oslobađanjem ima terapeutski efikasnu koncentraciju za povećanje brzine hoda pacijenta sa multiplom sklerozom.
24. Kompozicija aminopiridina sa produženim oslobađanjem za održavanje terapeutski efikasne koncentracije aminopiridina kod pacijenta sa multiplom sklerozom, naznačena time što je navedena kompozicija za primjenu kao tretman stabilnom dozom sa dnevnom terapeutskojem dozom od manje od 30 miligrama aminopiridina; i, pri čemu kompozicija aminopiridina sa produženim oslobađanjem ima terapeutski efikasnu koncentraciju za poboljšanje mišićne snage donjih ekstremiteta u pacijentu sa multiplom sklerozom.
25. Kompozicija aminopiridina sa produženim oslobađanjem za održavanje terapeutski efikasne koncentracije aminopiridina kod pacijenta sa multiplom sklerozom, naznačena time što je navedena kompozicija za primjenu kao tretman stabilnom dozom sa dnevnom terapeutskom dozom od manje od 30 miligrama aminopiridina; i, pri čemu kompozicija aminopiridina sa produženim oslobađanjem ima terapeutski efikasnu koncentraciju za poboljšanje mišićnog tonusa donjih ekstremiteta kod pacijenta sa multiplom sklerozom.
26. Kompozicija prema bilo kojem od patentnih zahtjeva 23 do 25, naznačena time što se koristi za primjenu dva puta na dan.
27. Kompozicija prema bilo kojem od patentnih zahtjeva 23 do 25, naznačena time što je navedeni tretman stabilnom dozom po trajanju duži od dva tjedna.
28. Kompozicija prema bilo kojem od patentnih zahtjeva 23 do 25, naznačena time što je navedeni aminopiridin jednak mono- aminopiridin ili diaminopiridin.
29. Kompozicija prema patentnom zahtjevu 28, naznačena time što je navedeni aminopiridin jednak 4-aminopiridin.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56089404P | 2004-04-09 | 2004-04-09 | |
| US11/102,559 US8354437B2 (en) | 2004-04-09 | 2005-04-08 | Method of using sustained release aminopyridine compositions |
| PCT/US2005/012427 WO2005099701A2 (en) | 2004-04-09 | 2005-04-11 | Methods of using sustained release aminopyridine compositions |
| EP05732613.4A EP1732548B2 (en) | 2004-04-09 | 2005-04-11 | Methods of using sustained release aminopyridine compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20110497T1 true HRP20110497T1 (hr) | 2011-08-31 |
| HRP20110497T4 HRP20110497T4 (hr) | 2024-03-29 |
Family
ID=35061389
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20110497TT HRP20110497T4 (hr) | 2004-04-09 | 2005-04-11 | Postupci za primjenu kompozicija aminopiridina sa produženim oslobađanjem |
| HRP20130424TT HRP20130424T4 (hr) | 2004-04-09 | 2013-05-14 | Postupci upotrebe sastava aminopiridina s odgođenim oslobađanjem |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130424TT HRP20130424T4 (hr) | 2004-04-09 | 2013-05-14 | Postupci upotrebe sastava aminopiridina s odgođenim oslobađanjem |
Country Status (21)
| Country | Link |
|---|---|
| US (13) | US8354437B2 (hr) |
| EP (5) | EP2422782A1 (hr) |
| JP (4) | JP5736100B2 (hr) |
| AT (1) | ATE511841T1 (hr) |
| AU (1) | AU2005232732B2 (hr) |
| CA (2) | CA2562277C (hr) |
| CY (4) | CY1111754T1 (hr) |
| DK (2) | DK2377536T4 (hr) |
| ES (2) | ES2746354T3 (hr) |
| FI (2) | FI1732548T4 (hr) |
| HK (1) | HK1162971A1 (hr) |
| HR (2) | HRP20110497T4 (hr) |
| HU (1) | HUE046320T2 (hr) |
| LU (2) | LU91933I2 (hr) |
| ME (2) | ME01836B (hr) |
| MX (3) | MX370434B (hr) |
| PL (2) | PL1732548T4 (hr) |
| PT (2) | PT1732548E (hr) |
| RS (2) | RS51808B2 (hr) |
| SI (2) | SI1732548T2 (hr) |
| WO (1) | WO2005099701A2 (hr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8007826B2 (en) | 2003-12-11 | 2011-08-30 | Acorda Therapeutics, Inc. | Sustained release aminopyridine composition |
| US8354437B2 (en) | 2004-04-09 | 2013-01-15 | Acorda Therapeutics, Inc. | Method of using sustained release aminopyridine compositions |
| AU2013206188B2 (en) * | 2005-09-23 | 2016-04-14 | Acorda Therapeutics, Inc. | Method, apparatus and software for identifying responders in a clinical environment |
| UY32109A (es) * | 2008-09-10 | 2010-04-30 | Acorda Therapeutics Inc | Métodos para utilizar composiciones de liberación sostenida de aminopiridina |
| CA2751581A1 (en) * | 2009-02-11 | 2010-08-19 | Acorda Therapeutics, Inc. | Compositions and methods for extended therapy with aminopyridines |
| JO3348B1 (ar) * | 2009-08-11 | 2019-03-13 | Acorda Therapeutics Inc | استخدام 4- بايريدين امينو لتحسين الادراك العصبي و/او التلف النفسي لدى مرضى يعانون من نقص النُخاعين وغير ذلك من امراض الجهاز العصبي |
| TW201125562A (en) * | 2009-09-04 | 2011-08-01 | Acorda Therapeutics Inc | Sustained release fampridine treatment in patients with multiple sclerosis |
| US20130030025A1 (en) * | 2011-01-28 | 2013-01-31 | Wessel Thomas C | Use of potassium channel blockers to treat cerebral palsy |
| US8924325B1 (en) * | 2011-02-08 | 2014-12-30 | Lockheed Martin Corporation | Computerized target hostility determination and countermeasure |
| CA2840591A1 (en) | 2011-06-30 | 2013-01-03 | Biomarin Pharmaceuticals, Inc. | Methods of administering 3,4-diaminopyridine |
| TWI592156B (zh) | 2011-10-04 | 2017-07-21 | 艾可達醫療公司 | 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法 |
| EA201491522A1 (ru) * | 2012-02-13 | 2014-12-30 | Акорда Терапьютикс, Инк. | Способы лечения нарушения походки и/или равновесия у пациентов с рассеянным склерозом с использованием аминопиридина |
| WO2014028387A1 (en) | 2012-08-13 | 2014-02-20 | Acorda Therapeutics, Inc. | Methods for improving walking capacity in patients with multiple sclerosis using an aminopyridine |
| WO2014093475A1 (en) | 2012-12-11 | 2014-06-19 | Acorda Therapeutics, Inc. | Methods for treating parkinson's disease using aminopyridines |
| SG11201507371RA (en) | 2013-03-14 | 2015-10-29 | Alkermes Pharma Ireland Ltd | Prodrugs of fumarates and their use in treating various deseases |
| US9993429B2 (en) * | 2013-03-15 | 2018-06-12 | University Of Rochester | Composition and methods for the treatment of peripheral nerve injury |
| US20160058743A1 (en) | 2013-04-15 | 2016-03-03 | Acorda Therapeutics, Inc. | Methods for treating sensorimotor impairments associated with certain types of stroke using aminopyridines |
| CA2972179C (en) | 2015-02-08 | 2021-10-26 | Alkermes Pharma Ireland Limited | Monomethylfumarate prodrug compositions |
| RU2580837C1 (ru) * | 2015-05-05 | 2016-04-10 | Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Московский Физико-Технический Институт (Государственный Университет)" | Кристаллогидрат 4-аминопиридина, способ его получения, фармацевтическая композиция и способ лечения и/или профилактики на её основе |
| CN106511293B (zh) | 2015-09-11 | 2020-08-04 | 法德生技药品股份有限公司 | 含有达方吡啶的缓释口服制剂及其用途 |
| WO2017058869A1 (en) | 2015-09-29 | 2017-04-06 | Acorda Therapeutics, Inc. | Sustained release compositions of 4-aminopyridine |
| CA3059180C (en) | 2017-04-06 | 2023-10-17 | Acorda Therapeutics, Inc. | Sustained release compositions of 4-aminopyridine |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1082804A (en) | 1912-11-19 | 1913-12-30 | Gerald G Griffin | Confetti-machine. |
| US3065143A (en) | 1960-04-19 | 1962-11-20 | Richardson Merrell Inc | Sustained release tablet |
| CH415963A (de) | 1964-09-04 | 1966-06-30 | Wander Ag Dr A | Masse zur Herstellung von Tabletten mit protrahierter Wirkung |
| US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US4508715A (en) * | 1981-07-01 | 1985-04-02 | University Of Georgia Research Foundation, Inc. | Antagonism of central nervous system drugs by the administration of 4-aminopyridine alone or in combination with other drugs |
| US4386095A (en) * | 1982-02-22 | 1983-05-31 | Cornell Research Foundation, Inc. | Diaminopyridines to improve cognition |
| IE53703B1 (en) | 1982-12-13 | 1989-01-18 | Elan Corp Plc | Drug delivery device |
| IE54286B1 (en) | 1983-01-18 | 1989-08-16 | Elan Corp Plc | Drug delivery device |
| US4851230A (en) * | 1983-04-07 | 1989-07-25 | Bristol-Myers Company | Capsule shaped tablets |
| IE56459B1 (en) | 1983-12-21 | 1991-08-14 | Elan Corp Ltd | Controlled absorption pharmaceutical formulation |
| IE56999B1 (en) * | 1983-12-22 | 1992-03-11 | Elan Corp Plc | Pharmaceutical formulation |
| US4894240A (en) * | 1983-12-22 | 1990-01-16 | Elan Corporation Plc | Controlled absorption diltiazem formulation for once-daily administration |
| US4562196A (en) | 1984-04-06 | 1985-12-31 | Nelson Research & Development | 2,4-Diaminopyridine as a pharmacologic agent |
| JPS6124516A (ja) | 1984-07-12 | 1986-02-03 | Fujisawa Pharmaceut Co Ltd | 持続性錠剤 |
| US4812447A (en) | 1985-10-22 | 1989-03-14 | City Of Hope | Method for the treatment of nervous system degeneration |
| US4760092A (en) | 1985-10-29 | 1988-07-26 | The Rockefeller University | Treatment of demyelinating diseases |
| US4832957A (en) | 1987-12-11 | 1989-05-23 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| IL86170A (en) * | 1987-05-01 | 1992-12-01 | Elan Transdermal Ltd | Preparations and compositions comprising nicotine for percutaneous administration |
| IE64726B1 (en) | 1987-11-20 | 1995-08-23 | Elan Corp Plc | Pharmaceutical formulations for preventing drug tolerance |
| FI895821A0 (fi) * | 1988-12-07 | 1989-12-05 | Wellcome Found | Farmaceutiskt aktiva cns foereningar. |
| US4948581A (en) | 1989-02-17 | 1990-08-14 | Dojin Iyaku-Kako Co., Ltd. | Long acting diclofenac sodium preparation |
| IE82916B1 (en) | 1990-11-02 | 2003-06-11 | Elan Corp Plc | Formulations and their use in the treatment of neurological diseases |
| TW200462B (hr) * | 1990-09-27 | 1993-02-21 | Hoechst Roussel Pharma | |
| CA2085785C (en) | 1992-12-18 | 2005-03-15 | Robert R. Hansebout | The use of 4-aminopyridine in the treatment of a neurological condition |
| DE4321030A1 (de) * | 1993-06-24 | 1995-01-05 | Bayer Ag | 4-bicyclisch substituierte Dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimittel |
| US5451409A (en) | 1993-11-22 | 1995-09-19 | Rencher; William F. | Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends |
| KR100354702B1 (ko) | 1993-11-23 | 2002-12-28 | 유로-셀티크 소시에떼 아노뉨 | 약학조성물의제조방법및서방형조성물 |
| US5952357A (en) * | 1993-12-23 | 1999-09-14 | Cornell Research Foundation, Inc. | Treating diseases of the anterior horn cells |
| US6284473B1 (en) * | 1995-10-02 | 2001-09-04 | Uab Research Foundation | P-cresol sulfate, a component of urinary myelin basic protein-like material, as a correlate of multiple sclerosis status |
| US7179486B1 (en) | 1997-04-01 | 2007-02-20 | Nostrum Pharmaceuticals, Inc. | Process for preparing sustained release tablets |
| US6288026B1 (en) * | 1999-02-24 | 2001-09-11 | Heinrich Exner | Process and composition for treating diseases with an oil-in-water emulsion |
| US6600399B1 (en) | 2002-02-05 | 2003-07-29 | Roland Pierre Trandafir | Transducer motor/generator assembly |
| WO2004082684A1 (en) | 2003-03-17 | 2004-09-30 | Acorda Therapeutics | Stable oral formulations of aminopyridines and uses thereof |
| WO2004087160A1 (en) * | 2003-04-03 | 2004-10-14 | Prana Biotechnology Ltd | Treatment of neurological conditions |
| WO2005011605A2 (en) * | 2003-08-01 | 2005-02-10 | Medarex, Inc. | Combination therapies for multiple sclerosis |
| US8007826B2 (en) | 2003-12-11 | 2011-08-30 | Acorda Therapeutics, Inc. | Sustained release aminopyridine composition |
| US8354437B2 (en) | 2004-04-09 | 2013-01-15 | Acorda Therapeutics, Inc. | Method of using sustained release aminopyridine compositions |
| US20060276537A1 (en) * | 2005-06-01 | 2006-12-07 | Tamar Goren | Use of ladostigil for the treatment of multiple sclerosis |
| AU2006292064A1 (en) | 2005-09-23 | 2007-03-29 | Acorda Therapeutics, Inc. | Method, apparatus and software for identifying responders in a clinical environment |
| TWM331106U (en) * | 2007-11-12 | 2008-04-21 | Syspotek Corp | Solution counter with temperature sensor |
| UY32109A (es) | 2008-09-10 | 2010-04-30 | Acorda Therapeutics Inc | Métodos para utilizar composiciones de liberación sostenida de aminopiridina |
| WO2010090730A1 (en) | 2009-02-03 | 2010-08-12 | Acorda Therapeutics, Inc. | Method, apparatus and software for identifying responders in a clinical environment |
| CA2751581A1 (en) | 2009-02-11 | 2010-08-19 | Acorda Therapeutics, Inc. | Compositions and methods for extended therapy with aminopyridines |
| JO3348B1 (ar) | 2009-08-11 | 2019-03-13 | Acorda Therapeutics Inc | استخدام 4- بايريدين امينو لتحسين الادراك العصبي و/او التلف النفسي لدى مرضى يعانون من نقص النُخاعين وغير ذلك من امراض الجهاز العصبي |
| TW201125562A (en) | 2009-09-04 | 2011-08-01 | Acorda Therapeutics Inc | Sustained release fampridine treatment in patients with multiple sclerosis |
| US10255905B2 (en) | 2016-06-10 | 2019-04-09 | Google Llc | Predicting pronunciations with word stress |
-
2005
- 2005-04-08 US US11/102,559 patent/US8354437B2/en active Active
- 2005-04-11 EP EP20110168901 patent/EP2422782A1/en not_active Withdrawn
- 2005-04-11 EP EP05732613.4A patent/EP1732548B2/en active Active
- 2005-04-11 EP EP11179067.1A patent/EP2460521B1/en active Active
- 2005-04-11 RS RS20110321A patent/RS51808B2/sr unknown
- 2005-04-11 DK DK11160247.0T patent/DK2377536T4/da active
- 2005-04-11 RS RS20130183A patent/RS53371B2/sr unknown
- 2005-04-11 ME MEP-2013-48A patent/ME01836B/me unknown
- 2005-04-11 PT PT05732613T patent/PT1732548E/pt unknown
- 2005-04-11 EP EP11160247.0A patent/EP2377536B2/en active Active
- 2005-04-11 AT AT05732613T patent/ATE511841T1/de active
- 2005-04-11 DK DK05732613.4T patent/DK1732548T4/da active
- 2005-04-11 HU HUE11179067A patent/HUE046320T2/hu unknown
- 2005-04-11 MX MX2015004339A patent/MX370434B/es unknown
- 2005-04-11 PT PT111602470T patent/PT2377536E/pt unknown
- 2005-04-11 ES ES11179067T patent/ES2746354T3/es active Active
- 2005-04-11 ES ES05732613T patent/ES2367707T5/es active Active
- 2005-04-11 CA CA2562277A patent/CA2562277C/en active Active
- 2005-04-11 PL PL05732613T patent/PL1732548T4/pl unknown
- 2005-04-11 HR HRP20110497TT patent/HRP20110497T4/hr unknown
- 2005-04-11 EP EP21170762.5A patent/EP3922248A1/en active Pending
- 2005-04-11 PL PL11160247.0T patent/PL2377536T5/pl unknown
- 2005-04-11 WO PCT/US2005/012427 patent/WO2005099701A2/en active Application Filing
- 2005-04-11 CA CA2870734A patent/CA2870734C/en active Active
- 2005-04-11 JP JP2007507570A patent/JP5736100B2/ja active Active
- 2005-04-11 MX MXPA06011648A patent/MXPA06011648A/es active IP Right Grant
- 2005-04-11 SI SI200531307T patent/SI1732548T2/sl unknown
- 2005-04-11 ME MEP-2011-321A patent/ME01721B/me unknown
- 2005-04-11 AU AU2005232732A patent/AU2005232732B2/en active Active
- 2005-04-11 SI SI200531728T patent/SI2377536T2/sl unknown
-
2006
- 2006-10-09 MX MX2019015036A patent/MX2019015036A/es unknown
-
2010
- 2010-06-25 US US12/824,135 patent/US20110166188A1/en not_active Abandoned
- 2010-06-25 US US12/824,136 patent/US20110166189A1/en not_active Abandoned
- 2010-06-25 US US12/824,133 patent/US20110166187A1/en not_active Abandoned
-
2011
- 2011-08-09 CY CY20111100757T patent/CY1111754T1/el unknown
- 2011-11-18 US US13/299,969 patent/US8440703B2/en active Active
-
2012
- 2012-01-18 LU LU91933C patent/LU91933I2/fr unknown
- 2012-01-19 CY CY2012004C patent/CY2012004I2/el unknown
- 2012-01-19 FI FIEP05732613.4T patent/FI1732548T4/fi active
- 2012-03-02 US US13/410,388 patent/US20120164078A1/en active Pending
- 2012-04-18 HK HK12103854.5A patent/HK1162971A1/xx active IP Right Maintenance
- 2012-04-25 JP JP2012100498A patent/JP2012188427A/ja active Pending
-
2013
- 2013-03-14 US US13/829,221 patent/US20140039015A1/en not_active Abandoned
- 2013-04-29 CY CY20131100351T patent/CY1114073T1/el unknown
- 2013-05-14 HR HRP20130424TT patent/HRP20130424T4/hr unknown
- 2013-08-13 FI FIC20130042C patent/FIC20130042I1/fi unknown
- 2013-09-03 LU LU92275C patent/LU92275I2/xx unknown
- 2013-09-05 CY CY2013035C patent/CY2013035I1/el unknown
-
2014
- 2014-11-03 US US14/531,191 patent/US20150080436A1/en not_active Abandoned
- 2014-12-24 JP JP2014259950A patent/JP5914626B2/ja active Active
-
2015
- 2015-06-05 JP JP2015114746A patent/JP2015157861A/ja not_active Withdrawn
-
2016
- 2016-03-23 US US15/079,010 patent/US20160199358A1/en not_active Abandoned
- 2016-11-04 US US15/344,096 patent/US20170071924A1/en not_active Abandoned
-
2017
- 2017-04-07 US US15/482,426 patent/US9925173B2/en active Active
- 2017-04-07 US US15/482,432 patent/US20170273960A1/en not_active Abandoned
-
2018
- 2018-03-12 US US15/918,931 patent/US20180200241A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110497T1 (hr) | Postupci za primjenu kompozicija aminopiridina sa produženim oslobađanjem | |
| MEP36608A (en) | Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics | |
| EA200800783A1 (ru) | Композиция тразодона для введения один раз в день | |
| PL372809A1 (en) | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof | |
| BRPI0418939A (pt) | derivados de nicotinamida e sua utilização como agentes terapêuticos | |
| BRPI0411825B8 (pt) | inibidores de p38 quinase a base de heterociclo de 5 elementos, seus processos de preparação e seus usos, bem como composição farmacêutica | |
| NO20064186L (no) | Substituerte pyrazolin sammensetninger for a redusere triglycerider i blod | |
| RS53591B1 (en) | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF INTERNAL HEARING DISORDERS | |
| EE05287B1 (et) | Tsklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon | |
| RS52199B (en) | PHARMACEUTICAL COMPOSITIONS OF THE NEUROACTIVE STEROID AND THEIR USE | |
| HRP20070079A2 (hr) | Fosfonatni analozi spojeva koji inhibiraju hiv | |
| MA28008A1 (fr) | Derives pyridyle et leur utilisation en tant qu'agents therapeutiques | |
| GEP20053510B (en) | Substituted Pyrrolopyridinone Derivatives Useful as Phosphodiesterase Inhibitors | |
| RS50303B (sr) | Farmaceutska kompozicija nimesulida sa kontrolisanim oslobađanjem | |
| SE0401345D0 (sv) | Therapeutic compounds: Pyridine as scaffold | |
| ATE364595T1 (de) | Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika | |
| NZ595046A (en) | Compositions and methods for extended therapy with aminopyridines | |
| SE0004101D0 (sv) | New use | |
| ATE410152T1 (de) | Therapeutisches system mit amoxicillin und clavulansäure | |
| DE602004017514D1 (de) | Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davon | |
| ATE477021T1 (de) | 1,3,5-triazepin-dionen zur behandlung von malaria | |
| SE0402029D0 (sv) | Prostaglandin a derivatieves for the treatment of psoriasis | |
| AR075414A1 (es) | Composiciones y metodos para terapia extendida con aminopiridinas | |
| ATE429905T1 (de) | Pharmazeutische zusammensetzung, enthaltend oxcarbazepin mit kontrollierter wirkstofffreisetzung |